An FDA advisory panel approves Novartis' (NVS) lung drug indacaterol in a 75mcg dose, but votes...

|About: Novartis AG (NVS)|By:, SA News Editor

An FDA advisory panel approves Novartis' (NVS) lung drug indacaterol in a 75mcg dose, but votes against the 150mcg dose used in Europe. The mixed approval clouds prospects for QVA149, a Novartis drug with potential sales of $5B annually if approved but which relies on higher doses of indacaterol.